Recombinant Bovine Probable palmitoyltransferase ZDHHC21 (ZDHHC21)

What are the known functional domains of ZDHHC21 and how do they relate to its enzymatic activity?

ZDHHC21 contains the characteristic DHHC domain (Asp-His-His-Cys) that defines the ZDHHC family of palmitoyl S-acyltransferases. This catalytic domain is essential for its palmitoyltransferase activity, facilitating the transfer of palmitate to specific cysteine residues on target proteins. Research has identified ZDHHC21 as functionally significant in:

• Mediating S-palmitoylation of FASN at Cys1317, resulting in decreased protein stability and reduced fatty acid synthesis

• Palmitoylating serotonin receptor 5-HT1A, with direct evidence of interaction between the two proteins

The zinc finger structure within the DHHC domain facilitates substrate recognition and binding, making it critical for ZDHHC21's specificity toward its target proteins.

How is ZDHHC21 different from other members of the ZDHHC family?

While ZDHHC21 shares the characteristic DHHC catalytic domain with other family members, it displays several distinguishing features:

• Subcellular localization: ZDHHC21 is primarily localized to the Golgi apparatus, unlike some family members such as ZDHHC5 which resides at the plasma membrane

• Substrate specificity: ZDHHC21 shows preferential palmitoylation activity toward specific proteins including FASN and 5-HT1AR

• Sequence homology: ZDHHC21 exhibits relatively low sequence homology with other ZDHHC family members (approximately 26-29% homology with ZDHHC5 and ZDHHC9), while maintaining high conservation (about 98% homology) between different mammalian species

This suggests that despite shared catalytic mechanisms, ZDHHC21 likely plays specialized physiological roles distinct from other family members.

What is the mechanism by which ZDHHC21 regulates FASN through palmitoylation?

ZDHHC21 exhibits a novel regulatory mechanism for FASN through the following pathway:

• Direct interaction: ZDHHC21 physically interacts with FASN as demonstrated through co-immunoprecipitation studies

• Site-specific palmitoylation: ZDHHC21 mediates the palmitoylation of FASN specifically at cysteine residue 1317 (Cys1317)

• Protein stability regulation: This palmitoylation event leads to decreased FASN protein stability, effectively reducing the cellular levels of functional FASN

• Metabolic consequences: The reduction in FASN stability results in decreased fatty acid synthesis within the cell

• Phenotypic outcome: The suppression of fatty acid synthesis contributes to inhibition of cell proliferation, particularly observed in DLBCL cells

This mechanism represents a previously unrecognized post-translational regulatory pathway for FASN, with significant implications for understanding lipid metabolism in both normal and pathological conditions.

How does ZDHHC21 expression correlate with clinical outcomes in cancer research?

Analysis of ZDHHC21 expression in clinical samples has revealed significant correlations with disease outcomes:

These findings suggest ZDHHC21 functions as a tumor suppressor in DLBCL, with potential utility as both a prognostic biomarker and therapeutic target.

What mechanisms regulate ZDHHC21 expression in normal and pathological states?

Research has identified several mechanisms that regulate ZDHHC21 expression:

• Genetic alterations:

  • Copy number variations: Heterozygous deletion in the ZDHHC21 locus occurs in approximately 6.25% of DLBCL cases

  • Mutations: Mutations in the ZDHHC21 locus are rare, observed in only 0.74% of DLBCL cases

• Epigenetic regulation:

  • DNA methylation: Methylation levels at specific CpG sites (probes cg01785060 and cg00775695) negatively correlate with ZDHHC21 expression levels

• Transcriptional regulation:

  • Transcription factor binding: The ZDHHC21 promoter contains potential binding sites for NFKB1, NFKB2, and STAT3

  • Subtype-specific correlation: NFKB1 and NFKB2 expression negatively correlates with ZDHHC21 expression in ABC subtype DLBCL, while STAT3 expression negatively correlates with ZDHHC21 expression in GCB subtype DLBCL

These diverse regulatory mechanisms suggest complex control of ZDHHC21 expression that may be exploited therapeutically in disease contexts.

What are the optimal conditions for reconstitution and storage of recombinant bovine ZDHHC21?

For optimal activity and stability of recombinant bovine ZDHHC21:

• Reconstitution protocol:

  • Briefly centrifuge the vial prior to opening to bring contents to the bottom

  • Reconstitute the lyophilized protein in deionized sterile water to a concentration of 0.1-1.0 mg/mL

  • Add glycerol to a final concentration of 5-50% (recommended 50% for long-term storage)

• Storage conditions:

  • Store reconstituted protein in aliquots at -20°C/-80°C

  • Avoid repeated freeze-thaw cycles as they significantly reduce protein activity

  • For short-term use, working aliquots may be stored at 4°C for up to one week

• Buffer considerations:

  • The protein is supplied in Tris/PBS-based buffer containing 6% Trehalose at pH 8.0

Adherence to these guidelines ensures maximum retention of ZDHHC21's enzymatic activity for experimental applications.

What assays can be used to measure ZDHHC21 palmitoyltransferase activity?

Several complementary approaches can be employed to assess ZDHHC21 palmitoyltransferase activity:

• Metabolic labeling:

  • Cells expressing ZDHHC21 and potential substrates are metabolically labeled with [9,10(n)³H]-palmitic acid

  • After immunoprecipitation of the substrate protein, incorporated radioactivity is measured to quantify palmitoylation

• Acyl-Biotin Exchange (ABE) technique:

  • This non-radioactive method involves:
    a) Blocking free thiols with N-ethylmaleimide
    b) Specific cleavage of thioester bonds with hydroxylamine
    c) Labeling newly exposed thiols with biotin
    d) Detection via Western blotting or mass spectrometry

• Functional readouts for specific substrates:

  • For 5-HT1AR: Measure G protein-coupled inwardly rectifying potassium (GIRK) currents using electrophysiological techniques

  • For FASN: Assess fatty acid synthesis rates and FASN protein stability through pulse-chase experiments

• Cell proliferation assays:

  • CCK8 (Cell Counting Kit-8) assay to measure cell viability as a downstream consequence of ZDHHC21-mediated palmitoylation of proteins involved in proliferation pathways

A combination of these approaches provides comprehensive assessment of ZDHHC21 activity.

What in vivo models are available for studying ZDHHC21 function?

Several animal models have been developed to study ZDHHC21 function in vivo:

• ZDHHC21-deficient mouse model (Zdhhc21^dep/dep):

  • Contains a spontaneous 3-bp deletion in the coding region of the Zdhhc21 gene

  • Results in non-functional ZDHHC21 protein

  • Shows impaired palmitoylation of 5-HT1AR in the brains of newborn mice

  • Exhibits developmental compensation, as adult mice show normalized palmitoylation levels

• Xenograft models:

  • BALB/c nude mice injected with DLBCL cells having modified ZDHHC21 expression

  • Protocol typically involves subcutaneous injection of 1×10^7 cells with altered ZDHHC21 expression

  • Tumor volumes measured every two days for approximately four weeks

  • Enables assessment of ZDHHC21's effect on tumor growth in vivo

• Pharmacological intervention models:

  • Treatment with lanatoside C, which interacts with ZDHHC21 and increases its protein stability

  • Allows for assessment of therapeutic targeting of the ZDHHC21/FASN axis

These models provide valuable platforms for investigating ZDHHC21's physiological and pathological roles in complex biological systems.

What technical considerations should be addressed when performing co-immunoprecipitation studies with ZDHHC21?

When conducting co-immunoprecipitation (co-IP) studies with ZDHHC21:

• Tag selection and positioning:

  • N-terminal tags (such as HA or GFP) are preferred as C-terminal modifications may interfere with the DHHC domain

  • For substrate proteins, consider potential interference of tags with palmitoylation sites

• Expression systems:

  • Neuroblastoma N1E cells have been successfully used for co-expression of ZDHHC21 and potential substrates

  • Consider using ZDHHC21's natural cellular environment (like B-cell lines for FASN interaction studies)

• Control experiments:

  • Include non-palmitoylating ZDHHC21 mutants as negative controls

  • Use known ZDHHC21 substrates (such as 5-HT1AR or FASN) as positive controls

  • Include immunoprecipitation with non-specific IgG to control for non-specific binding

• Detection methods:

  • Western blotting with specific antibodies for each protein

  • Consider palmitoylation state analysis in parallel using ABE or metabolic labeling to correlate interaction with enzymatic activity

These considerations help ensure specific and physiologically relevant detection of ZDHHC21-substrate interactions.

How might therapeutic targeting of ZDHHC21 be developed for cancer treatment?

Based on current research, several promising approaches for ZDHHC21-targeted therapeutics include:

• Small molecule enhancers:

  • Lanatoside C has been identified as an FDA-approved compound that interacts with ZDHHC21

  • It increases ZDHHC21 protein stability and decreases FASN expression

  • This contributes to suppression of DLBCL growth both in vitro and in vivo

• Substrate-specific approach:

  • Developing molecules that specifically enhance ZDHHC21-mediated palmitoylation of tumor suppressors

  • Targeting the ZDHHC21/FASN interaction interface to promote FASN palmitoylation and subsequent degradation

• Expression restoration strategies:

  • Targeting transcription factors (NFKB1, NFKB2, STAT3) that repress ZDHHC21 expression

  • Epigenetic approaches targeting methylation sites (cg01785060, cg00775695) that regulate ZDHHC21 expression

• Combination therapy potential:

  • Synergistic approaches combining ZDHHC21 activation with direct FASN inhibitors

  • Integration with standard lymphoma treatments to enhance efficacy and reduce resistance

These approaches represent promising avenues for translating ZDHHC21 research into clinical applications for DLBCL and potentially other cancers.

What is the developmental significance of ZDHHC21's role in receptor palmitoylation?

The developmental importance of ZDHHC21 is highlighted by several observations:

Further research is needed to fully elucidate the temporal dynamics of ZDHHC21 function during development and the mechanisms underlying compensatory responses in its absence.